Jorge Vasconez-Gonzalez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jorge Vasconez-Gonzalez has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Esteban Ortiz-Prado
One Health Research Group, Universidad de Las Américas, Quito, Ecuador
7 shared publications - Juan Sebastian Izquierdo-Condoy
One Health Research Group, Universidad de Las Américas, Quito 170124, Ecuador
6 shared publications - Elías David Guamán Charco
Hospital General “Marco Vinicio Iza”, Ministerio de Salud Pública, Nueva Loja 170702, Ecuador
2 shared publications - Ana Gabriela Finke Barriga
Department of Internal Medicine, Hospital Metropolitano, Quito, Ecuador
1 shared publication - Ana Sofia Cepeda-Zaldumbide
Centro de Salud, Ministerio de Salud Pública, Lasso 050102, Cotopaxi, Ecuador
1 shared publication - Andrea Cristina Aragón-Jácome
Centro de Salud, Ministerio de Salud Pública, Valencia 120610, Los Rios, Ecuador
1 shared publication
Latest Publications
- Open Access
- 24 October 2026
- Published by MDPI AG in Healthcare
- Vol. 14 (21) , 3606
When AI Becomes the First Consultant: Implications for Medical Training
Artificial intelligence enables rapid and easy access to scientific information, allowing for quick diagnostic outputs. As a result, it is becoming a primary source of consultation for medical students. This shift is transforming how clinical knowledge is applied and raises concerns about the development of clinical reasoning. Excessive reliance on these tools may reduce students’ active engagement, limit their diagnostic creativity, and promote a more passive learning style. Furthermore, AI performance can be limited in complex or uncertain clinical scenarios. Therefore, AI should be used as a complementary educational tool that supports the development of autonomous clinical skills, rather than replacing clinical reasoning. It is also essential to teach medical students the responsible use of these technologies, as well as the potential consequences of their misuse.
- 24 October 2026
- Published by MDPI AG in Healthcare
- Vol. 14 (21) , 3606
Open AccessWhen AI Becomes the First Consultant: Implications for Medical Training
Artificial intelligence enables rapid and easy access to scientific information, allowing for quick diagnostic outputs. As a result, it is becoming a primary source of consultation for medical students. This shift is transforming how clinical knowledge is applied and raises concerns about the development of clinical reasoning. Excessive reliance on these tools may reduce students’ active engagement, limit their diagnostic creativity, and promote a more passive learning style. Furthermore, AI performance can be limited in complex or uncertain clinical scenarios. Therefore, AI should be used as a complementary educational tool that supports the development of autonomous clinical skills, rather than replacing clinical reasoning. It is also essential to teach medical students the responsible use of these technologies, as well as the potential consequences of their misuse.
- Open Access
Clinical and Epidemiological Profile of Atrial Fibrillation in a High-Altitude Tertiary-Care Setting
Background and Objectives: Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and a major cause of stroke, heart failure, and death. Evidence on AF in Latin American and Andean tertiary-care settings remains limited. The objective was to describe the demographic and clinical profile, documented thromboembolic and bleeding risk, in-hospital management, and outcomes of adults with AF treated at a tertiary hospital located at 2850 m above sea level. Materials and Methods: We retrospectively reviewed unique adult patient records from January 2021 through December 2023 identified by ICD-10 code I48 and explicit clinician documentation of AF. Independent electrocardiographic adjudication was not performed. Demographics, comorbidities, chart-recorded AF category, risk scores, echocardiographic findings, in-hospital treatments, and outcomes were summarized descriptively. Results: Among 238 patients, mean age was 77.9 ± 13.3 years, 55.0% were male, and 97.1% were recorded as mestizo. Hypertension (58.0%) and heart failure (22.7%) were the most frequent comorbidities. CHA2DS2-VASc and HAS-BLED scores were documented for 199 patients (83.6%); their respective means were 3.3 ± 1.4 and 2.3 ± 1.1. Any anticoagulant was administered during hospitalization to 195 patients (81.9%), but previous and discharge therapy, indications, contraindications, dosing, and temporary interruptions were not consistently available. Five patients died in hospital (2.1%). Secondary exploratory comparisons by survival status were hypothesis-generating, and none remained significant after false-discovery-rate correction. Conclusions: This cohort describes an older, comorbid population treated at a hospital situated at high altitude. The study does not establish an altitude-related AF phenotype, the appropriateness of chronic anticoagulation, or prognostic factors for mortality. Prospective multicentre studies with adjudicated AF, individual altitude exposure, oxygenation and haematologic measures, and longitudinal treatment data are warranted.
Open AccessClinical and Epidemiological Profile of Atrial Fibrillation in a High-Altitude Tertiary-Care Setting
Background and Objectives: Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and a major cause of stroke, heart failure, and death. Evidence on AF in Latin American and Andean tertiary-care settings remains limited. The objective was to describe the demographic and clinical profile, documented thromboembolic and bleeding risk, in-hospital management, and outcomes of adults with AF treated at a tertiary hospital located at 2850 m above sea level. Materials and Methods: We retrospectively reviewed unique adult patient records from January 2021 through December 2023 identified by ICD-10 code I48 and explicit clinician documentation of AF. Independent electrocardiographic adjudication was not performed. Demographics, comorbidities, chart-recorded AF category, risk scores, echocardiographic findings, in-hospital treatments, and outcomes were summarized descriptively. Results: Among 238 patients, mean age was 77.9 ± 13.3 years, 55.0% were male, and 97.1% were recorded as mestizo. Hypertension (58.0%) and heart failure (22.7%) were the most frequent comorbidities. CHA2DS2-VASc and HAS-BLED scores were documented for 199 patients (83.6%); their respective means were 3.3 ± 1.4 and 2.3 ± 1.1. Any anticoagulant was administered during hospitalization to 195 patients (81.9%), but previous and discharge therapy, indications, contraindications, dosing, and temporary interruptions were not consistently available. Five patients died in hospital (2.1%). Secondary exploratory comparisons by survival status were hypothesis-generating, and none remained significant after false-discovery-rate correction. Conclusions: This cohort describes an older, comorbid population treated at a hospital situated at high altitude. The study does not establish an altitude-related AF phenotype, the appropriateness of chronic anticoagulation, or prognostic factors for mortality. Prospective multicentre studies with adjudicated AF, individual altitude exposure, oxygenation and haematologic measures, and longitudinal treatment data are warranted.
- Open Access
- 30 June 2026
- Published by MDPI AG in Medical Sciences
- Vol. 14 (3) , 363
Variation of the Neutrophil-to-Lymphocyte Ratio and Mean Platelet Volume in a Multicenter Study of Critically Ill Patients with COVID-19 Living at Different Altitudes
Background: Evidence on the prognostic utility of biological markers in critically ill patients with COVID-19 across different geographic altitudes remains limited. Objectives: The aim of this study was to determine the prognostic value of inflammatory and hematological markers, particularly the neutrophil-to-lymphocyte ratio (NLR) and mean platelet volume (MPV), for mortality risk in critically ill patients with COVID-19 receiving invasive mechanical ventilation and living at different geographic altitudes. Methods: A multicenter retrospective cohort study was conducted using secondary data from a clinical database. A total of 362 critically ill patients with COVID-19 admitted to intensive care units (ICUs) between April 2020 and March 2022 were included. Patients were treated at three hospitals in Ecuador located at different altitudes: sea level (4 m above sea level [masl]), moderate altitude (2200 masl), and high altitude (2850 masl). Clinical, laboratory, and outcome data were obtained from electronic medical records. Results: The mean age was 54.44 years, and 71.27% of patients were male. Post hoc, altitude-stratified NLR and MPV thresholds were associated with increased odds of ICU mortality: at sea level, NLR ≥ 12.50 and MPV ≥ 8.80 fL; at moderate altitude, NLR ≥ 11.50 and MPV ≥ 9.80 fL; and at high altitude, NLR ≥ 16.30 and MPV ≥ 9.00 fL. Conclusions: In mechanically ventilated patients with critical COVID-19, NLR and MPV values above post hoc, altitude-stratified cutoff points were associated with higher ICU mortality. However, because each altitude stratum corresponded to a different hospital and these thresholds were not ROC-derived or internally/externally validated, these findings should be interpreted as exploratory and hypothesis-generating.
- 30 June 2026
- Published by MDPI AG in Medical Sciences
- Vol. 14 (3) , 363
Open AccessVariation of the Neutrophil-to-Lymphocyte Ratio and Mean Platelet Volume in a Multicenter Study of Critically Ill Patients with COVID-19 Living at Different Altitudes
Background: Evidence on the prognostic utility of biological markers in critically ill patients with COVID-19 across different geographic altitudes remains limited. Objectives: The aim of this study was to determine the prognostic value of inflammatory and hematological markers, particularly the neutrophil-to-lymphocyte ratio (NLR) and mean platelet volume (MPV), for mortality risk in critically ill patients with COVID-19 receiving invasive mechanical ventilation and living at different geographic altitudes. Methods: A multicenter retrospective cohort study was conducted using secondary data from a clinical database. A total of 362 critically ill patients with COVID-19 admitted to intensive care units (ICUs) between April 2020 and March 2022 were included. Patients were treated at three hospitals in Ecuador located at different altitudes: sea level (4 m above sea level [masl]), moderate altitude (2200 masl), and high altitude (2850 masl). Clinical, laboratory, and outcome data were obtained from electronic medical records. Results: The mean age was 54.44 years, and 71.27% of patients were male. Post hoc, altitude-stratified NLR and MPV thresholds were associated with increased odds of ICU mortality: at sea level, NLR ≥ 12.50 and MPV ≥ 8.80 fL; at moderate altitude, NLR ≥ 11.50 and MPV ≥ 9.80 fL; and at high altitude, NLR ≥ 16.30 and MPV ≥ 9.00 fL. Conclusions: In mechanically ventilated patients with critical COVID-19, NLR and MPV values above post hoc, altitude-stratified cutoff points were associated with higher ICU mortality. However, because each altitude stratum corresponded to a different hospital and these thresholds were not ROC-derived or internally/externally validated, these findings should be interpreted as exploratory and hypothesis-generating.
- Open Access
- 27 February 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (5) , 1792
Minoxidil Beyond Hair: A Comprehensive Review of Its Effects on Nail Growth
Minoxidil is a well-established treatment for hair loss, known for its vasodilatory properties and effects on dermal papilla cells. Recently, interest has emerged regarding its potential role in promoting nail growth, both in healthy individuals and in those with nail dystrophies. The objective of this review was to synthesize and critically analyze the available evidence on the effects of topical and oral minoxidil on nail growth, including proposed mechanisms of action, clinical outcomes, and safety. A narrative literature review was conducted using studies published in indexed journals that evaluated the pharmacological effects of minoxidil on the nail unit. Mechanistic data were extracted from in vitro and in vivo models, while clinical results were compiled from pilot studies, case reports, and trials evaluating nail growth in both healthy and pathologic conditions. Proposed mechanisms include vasodilation, increased VEGF expression, and hypothesized involvement of pro-growth pathways (e.g., Wnt/β-catenin), largely extrapolated from hair follicle biology; direct nail-matrix-specific mechanistic evidence remains limited. Clinical studies with 5% topical minoxidil have shown increases in nail growth rate ranging from 13% to 19% over 28 days, while oral minoxidil (2.5 mg) resulted in an approximately 50% increase in nail growth speed in small studies. Evidence also suggests improvements in nail strength and appearance. Adverse effects were minimal, with no significant changes in blood pressure and only modest increases in heart rate with oral formulations. Although evidence remains limited, preliminary findings suggest a potential role for minoxidil in enhancing nail growth, particularly in cases of slowed growth or nail dystrophy. More robust, large-scale studies are needed to confirm efficacy, determine optimal formulations, and establish long-term safety. Given its accessibility and tolerability, minoxidil may represent a promising off-label adjunct for nail growth modulation.
- 27 February 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (5) , 1792
Open AccessMinoxidil Beyond Hair: A Comprehensive Review of Its Effects on Nail Growth
Minoxidil is a well-established treatment for hair loss, known for its vasodilatory properties and effects on dermal papilla cells. Recently, interest has emerged regarding its potential role in promoting nail growth, both in healthy individuals and in those with nail dystrophies. The objective of this review was to synthesize and critically analyze the available evidence on the effects of topical and oral minoxidil on nail growth, including proposed mechanisms of action, clinical outcomes, and safety. A narrative literature review was conducted using studies published in indexed journals that evaluated the pharmacological effects of minoxidil on the nail unit. Mechanistic data were extracted from in vitro and in vivo models, while clinical results were compiled from pilot studies, case reports, and trials evaluating nail growth in both healthy and pathologic conditions. Proposed mechanisms include vasodilation, increased VEGF expression, and hypothesized involvement of pro-growth pathways (e.g., Wnt/β-catenin), largely extrapolated from hair follicle biology; direct nail-matrix-specific mechanistic evidence remains limited. Clinical studies with 5% topical minoxidil have shown increases in nail growth rate ranging from 13% to 19% over 28 days, while oral minoxidil (2.5 mg) resulted in an approximately 50% increase in nail growth speed in small studies. Evidence also suggests improvements in nail strength and appearance. Adverse effects were minimal, with no significant changes in blood pressure and only modest increases in heart rate with oral formulations. Although evidence remains limited, preliminary findings suggest a potential role for minoxidil in enhancing nail growth, particularly in cases of slowed growth or nail dystrophy. More robust, large-scale studies are needed to confirm efficacy, determine optimal formulations, and establish long-term safety. Given its accessibility and tolerability, minoxidil may represent a promising off-label adjunct for nail growth modulation.
- Open Access
- 26 February 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (5) , 1756
An Unusual Presentation of Nicolau Syndrome in the Upper Limb: A Case Report from Northern Ecuadorian Amazonia
Nicolau syndrome, also known as embolia cutis medicamentosa, is a rare iatrogenic reaction that may occur following parenteral drug administration, including inadvertent intra-arterial or periarterial injection. Its pathophysiology remains poorly understood; however, several mechanisms have been proposed, including vasospasm, embolization, cytotoxic inflammation, and secondary tissue necrosis. We report the case of a 22-year-old transgender woman who received intravenous benzathine penicillin in the left arm without a medical prescription following a reactive syphilis screening performed outside a formal healthcare setting. She subsequently developed severe pain, livedoid dermatitis, pallor, distal cyanosis, and blister formation. Radial and brachial pulses remained palpable, and Doppler ultrasonography revealed no evidence of arterial or venous thrombosis. Medical management included daily wound care, anticoagulation, corticosteroids, peripheral vasodilators, antibiotic therapy, and analgesia. The patient was hospitalized for nine days, with partial clinical improvement. However, persistent distal ischemic changes involving the second through fifth fingers raised concern for evolving necrosis and potential amputation. After counseling regarding these risks, the patient requested voluntary discharge. This case underscores the importance of safe medication administration and appropriate injection practices, particularly in low-resource settings. It also highlights the need for improved training of healthcare personnel to ensure early recognition and prompt management of Nicolau syndrome, as well as strengthened patient education to discourage self-medication and promote timely care by qualified healthcare professionals.
- 26 February 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (5) , 1756
Open AccessAn Unusual Presentation of Nicolau Syndrome in the Upper Limb: A Case Report from Northern Ecuadorian Amazonia
Nicolau syndrome, also known as embolia cutis medicamentosa, is a rare iatrogenic reaction that may occur following parenteral drug administration, including inadvertent intra-arterial or periarterial injection. Its pathophysiology remains poorly understood; however, several mechanisms have been proposed, including vasospasm, embolization, cytotoxic inflammation, and secondary tissue necrosis. We report the case of a 22-year-old transgender woman who received intravenous benzathine penicillin in the left arm without a medical prescription following a reactive syphilis screening performed outside a formal healthcare setting. She subsequently developed severe pain, livedoid dermatitis, pallor, distal cyanosis, and blister formation. Radial and brachial pulses remained palpable, and Doppler ultrasonography revealed no evidence of arterial or venous thrombosis. Medical management included daily wound care, anticoagulation, corticosteroids, peripheral vasodilators, antibiotic therapy, and analgesia. The patient was hospitalized for nine days, with partial clinical improvement. However, persistent distal ischemic changes involving the second through fifth fingers raised concern for evolving necrosis and potential amputation. After counseling regarding these risks, the patient requested voluntary discharge. This case underscores the importance of safe medication administration and appropriate injection practices, particularly in low-resource settings. It also highlights the need for improved training of healthcare personnel to ensure early recognition and prompt management of Nicolau syndrome, as well as strengthened patient education to discourage self-medication and promote timely care by qualified healthcare professionals.
- Open Access
- 7 January 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (2) , 456
Left Atrial Thrombus and Cardioembolic Stroke in Chagas Cardiomyopathy Presenting with Atrial Flutter: A Case Report
Background: Chagas disease, caused by Trypanosoma cruzi, remains endemic throughout Latin America but is increasingly reported in urban areas due to migration and vector adaptation. The cardiac form is the most severe manifestation, associated with arrhythmia, mural thrombus formation, and a high risk of cardioembolic events. Stroke secondary to Chagas cardiomyopathy is uncommon and poses diagnostic and therapeutic challenges. Case Presentation: A 58-year-old woman with serologic evidence of T. cruzi infection presented with sudden-onset dyspnea, oppressive chest pain, and left-sided weakness. Neurological examination revealed left brachiocrural hemiparesis and mild dysarthria (NIHSS = 9). Non-contrast cranial CT showed an acute infarct in the right middle cerebral artery territory (ASPECTS = 7). Electrocardiography demonstrated typical atrial flutter with variable conduction, and transthoracic echocardiography revealed a markedly dilated left atrium containing a mural thrombus and a left ventricular ejection fraction of 45%. Intravenous thrombolysis with alteplase (0.9 mg/kg) was administered within 4.5 h of symptom onset. Pharmacologic rhythm control was achieved using intravenous and oral amiodarone, followed by oral anticoagulation with warfarin (target INR 2.0–3.0) after excluding hemorrhagic transformation. The patient showed rapid neurological improvement (NIHSS reduction from 9 to 2) and was discharged on day 10 with minimal residual deficit (mRS = 1), sinus rhythm, and stable hemodynamics. Conclusions: This case highlights the rare coexistence of Chagas cardiomyopathy, atrial flutter, and cardioembolic stroke due to left atrial thrombus. Early recognition, adherence to evidence-based guidelines, and multidisciplinary management were key to achieving a favorable outcome. Timely diagnosis and intervention remain crucial to preventing severe complications in patients with Chagas disease.
- 7 January 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (2) , 456
Open AccessLeft Atrial Thrombus and Cardioembolic Stroke in Chagas Cardiomyopathy Presenting with Atrial Flutter: A Case Report
Background: Chagas disease, caused by Trypanosoma cruzi, remains endemic throughout Latin America but is increasingly reported in urban areas due to migration and vector adaptation. The cardiac form is the most severe manifestation, associated with arrhythmia, mural thrombus formation, and a high risk of cardioembolic events. Stroke secondary to Chagas cardiomyopathy is uncommon and poses diagnostic and therapeutic challenges. Case Presentation: A 58-year-old woman with serologic evidence of T. cruzi infection presented with sudden-onset dyspnea, oppressive chest pain, and left-sided weakness. Neurological examination revealed left brachiocrural hemiparesis and mild dysarthria (NIHSS = 9). Non-contrast cranial CT showed an acute infarct in the right middle cerebral artery territory (ASPECTS = 7). Electrocardiography demonstrated typical atrial flutter with variable conduction, and transthoracic echocardiography revealed a markedly dilated left atrium containing a mural thrombus and a left ventricular ejection fraction of 45%. Intravenous thrombolysis with alteplase (0.9 mg/kg) was administered within 4.5 h of symptom onset. Pharmacologic rhythm control was achieved using intravenous and oral amiodarone, followed by oral anticoagulation with warfarin (target INR 2.0–3.0) after excluding hemorrhagic transformation. The patient showed rapid neurological improvement (NIHSS reduction from 9 to 2) and was discharged on day 10 with minimal residual deficit (mRS = 1), sinus rhythm, and stable hemodynamics. Conclusions: This case highlights the rare coexistence of Chagas cardiomyopathy, atrial flutter, and cardioembolic stroke due to left atrial thrombus. Early recognition, adherence to evidence-based guidelines, and multidisciplinary management were key to achieving a favorable outcome. Timely diagnosis and intervention remain crucial to preventing severe complications in patients with Chagas disease.
- Open Access
Hansen’s Disease in Ecuador: Current Status, Knowledge Gaps, and Research Priorities: A Literature Review
Background: Hansen’s disease or leprosy is one of the 21 neglected tropical diseases (NTDs). In Ecuador, leprosy is considered eliminated as a public health problem; however, new cases are reported annually. Additionally, Mycobacterium leprae infection was detected in nine-banded armadillos across the country, suggesting a potential zoonotic reservoir. This literature review aims to provide an updated overview of the epidemiological situation of leprosy in Ecuador, identify knowledge gaps, and outline research priorities to support the development of a comprehensive national strategy for achieving zero autochthonous cases. Methods: This article analyses the current situation of leprosy in Ecuador based on international and national publications. A retrospective literature search using five international, regional, and national publications on leprosy published between 1954 and 2024 (70 years) with no restriction on language or publication date, was performed. Findings: Our review identified 28 publications with the earliest article dating back to 1954. Of these, 14 were published in international journals, 15 (53.6%) were in Spanish. Four nationwide studies documented leprosy cases across Ecuador’s three continental regions (Coast, Andes, and Amazon) with a predominance in the tropical coast. No cases have been reported from the Galápagos Islands. From 1983, Ecuador started multi-drug therapy. Data from the Ministry of Public Health (MoH) system identified 1539 incident cases, showing a significant decline in new cases from 2000 to 2024, with no cases in children. New cases detection rate by 100,000 inhabitants was 0.51 in 2019 according to the World Health Organization (WHO). No study has genotyped the Mycobacterium spp. in human cases, other animal species, or environment. According to the MoH, multibacillary leprosy accounts for 78.95% of diagnosed cases, with confirmation based on Ziehl–Neelsen staining and histopathology. No survey has assessed disabilities, knowledge, attitudes, and practices (KAP) or stigma related to leprosy. Research is needed on transmission routes, Mycobacterium genotyping, genetic susceptibility, and antibiotic resistance. BCG vaccination coverage fell to 75.3% in 2021. Cases are currently diagnosed and treated on an outpatient basis in large hospitals. Conclusions: This comprehensive review highlights persistent gaps in leprosy research and critical information, despite seven decades of documented cases in Ecuador. The disease is still endemic across the country, particularly at subnational level in the subtropics and tropics of the Pacific coast and the Amazon. There is a need for nationwide epidemiological research on reservoirs and the environment applying the One Health concept. Increased laboratory facilities and readily available official data are required to improve our understanding of leprosy in Ecuador. Strengthening community-level efforts is essential for Ecuador to meet the targets of the “WHO’s Towards Zero Leprosy: Strategy 2021–2030.”
Open AccessHansen’s Disease in Ecuador: Current Status, Knowledge Gaps, and Research Priorities: A Literature Review
Background: Hansen’s disease or leprosy is one of the 21 neglected tropical diseases (NTDs). In Ecuador, leprosy is considered eliminated as a public health problem; however, new cases are reported annually. Additionally, Mycobacterium leprae infection was detected in nine-banded armadillos across the country, suggesting a potential zoonotic reservoir. This literature review aims to provide an updated overview of the epidemiological situation of leprosy in Ecuador, identify knowledge gaps, and outline research priorities to support the development of a comprehensive national strategy for achieving zero autochthonous cases. Methods: This article analyses the current situation of leprosy in Ecuador based on international and national publications. A retrospective literature search using five international, regional, and national publications on leprosy published between 1954 and 2024 (70 years) with no restriction on language or publication date, was performed. Findings: Our review identified 28 publications with the earliest article dating back to 1954. Of these, 14 were published in international journals, 15 (53.6%) were in Spanish. Four nationwide studies documented leprosy cases across Ecuador’s three continental regions (Coast, Andes, and Amazon) with a predominance in the tropical coast. No cases have been reported from the Galápagos Islands. From 1983, Ecuador started multi-drug therapy. Data from the Ministry of Public Health (MoH) system identified 1539 incident cases, showing a significant decline in new cases from 2000 to 2024, with no cases in children. New cases detection rate by 100,000 inhabitants was 0.51 in 2019 according to the World Health Organization (WHO). No study has genotyped the Mycobacterium spp. in human cases, other animal species, or environment. According to the MoH, multibacillary leprosy accounts for 78.95% of diagnosed cases, with confirmation based on Ziehl–Neelsen staining and histopathology. No survey has assessed disabilities, knowledge, attitudes, and practices (KAP) or stigma related to leprosy. Research is needed on transmission routes, Mycobacterium genotyping, genetic susceptibility, and antibiotic resistance. BCG vaccination coverage fell to 75.3% in 2021. Cases are currently diagnosed and treated on an outpatient basis in large hospitals. Conclusions: This comprehensive review highlights persistent gaps in leprosy research and critical information, despite seven decades of documented cases in Ecuador. The disease is still endemic across the country, particularly at subnational level in the subtropics and tropics of the Pacific coast and the Amazon. There is a need for nationwide epidemiological research on reservoirs and the environment applying the One Health concept. Increased laboratory facilities and readily available official data are required to improve our understanding of leprosy in Ecuador. Strengthening community-level efforts is essential for Ecuador to meet the targets of the “WHO’s Towards Zero Leprosy: Strategy 2021–2030.”